Compare National Beverage Corp. (FIZZ) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

FIZZ trades at $32.09, up 3.78% on the day, but the stock faces bearish technical signals and mixed earnings results, with three of the last four quarters missing EPS estimates. The company maintains solid profitability with a 15.56% net income margin and a 34.03% ROE, while a recent special dividend of $3.25 per share reflects shareholder returns. However, revenue has stagnated around $1.2 billion annually, and analyst sentiment is cautious, with 50% of coverage recommending Sell.

The outlook for FIZZ is clouded by stalled growth and competitive pressures, particularly for its LaCroix brand. While valuation multiples like a P/E of 15.73 appear reasonable, the lack of revenue catalysts and bearish technical trends suggest limited near-term upside. Key risks include declining volumes and consumer weakness, requiring investors to weigh dividend returns against fundamental headwinds.

XRAY trades at $13.76, up 8.35% in 24 hours, with technical indicators showing a bullish trend. The stock has missed earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.36. Revenue declined to $3.68 billion in 2025, and the company reported a net loss of $598 million. Recent news highlights include distribution expansions and new AI-enabled product launches, while analyst sentiment remains mixed with a consensus price target of $13.33.

The outlook for XRAY is cautious due to persistent earnings misses and negative profitability, though technical momentum and strategic initiatives offer some upside potential. Key risks include margin pressure, high debt levels, and soft European demand. Investors should weigh the bullish technical signals against fundamental weaknesses before considering a position.